GeoVax Labs And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed slighty higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

MAIA Biotechnology

• The Trade: MAIA Biotechnology, Inc. MAIA Director Stan Smith acquired a total 10,000 shares an average price of $3.74. To acquire these shares, it cost around $37.4 thousand.
• What’s Happening: MAIA Biotechnology reported preliminary survival data in Part A of THIO-101 Phase 2 trial for non-small cell lung cancer.
• What MAIA Biotechnology Does: MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.

flooidCX

• The Trade: flooidCX Corp. FLCX CEO Dennis M Danzik acquired a total of 1,900 shares at an average price of $3.76. The insider spent around $7.14 to buy those shares.
• What’s Happening: The company’s stock jumped around 420% over the past month.
• What flooidCX Does: FlooidCX Corp acts as an online complaint resolution platform for consumers and businesses. The company offers unified communications and collaboration in online CRM solutions - GripeVine and Resolution1.

GeoVax Labs

• The Trade: GeoVax Labs, Inc. GOVX CFO Mark Reynolds acquired a total of 8,000 shares at an average price of $0.63. To acquire these shares, it cost around $5.04 thousand.
• What’s Happening: GeoVax announced expansion of next-generation COVID-19 vaccine rights to include omicron variants and use against orthopoxviruses.
• What GeoVax Labs Does: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.

Check This Out: Top 4 Tech And Telecom Stocks That May Plunge In Q2

Don’t forget to check out our premarket coverage here